The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens

Diagn Microbiol Infect Dis. 2018 Jan;90(1):64-66. doi: 10.1016/j.diagmicrobio.2017.09.011. Epub 2017 Sep 20.

Abstract

The in vitro antimicrobial activity of iclaprim, a novel diaminopyrimidine, against common respiratory bacteria remained unchanged in the presence of pulmonary surfactant (Survanta®) at concentrations that greatly antagonized the antimicrobial activity of daptomycin. These results indicate that iclaprim could be a potential treatment for pneumonia caused by susceptible and multidrug resistant bacteria.

Keywords: Iclaprim; Pneumonia; Surfactant; in vitro.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteria / drug effects*
  • Bacteria / isolation & purification
  • Drug Resistance, Multiple, Bacterial
  • Folic Acid Antagonists / pharmacology*
  • Humans
  • Microbial Sensitivity Tests
  • Pneumonia, Bacterial / drug therapy*
  • Pneumonia, Bacterial / microbiology
  • Pulmonary Surfactants / pharmacology*
  • Pyrimidines / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Folic Acid Antagonists
  • Pulmonary Surfactants
  • Pyrimidines
  • iclaprim